1
|
Panayotacopoulou MT, Papageorgiou I, Pagida M, Katsogridaki AE, Chrysanthou-Piterou M, Valous NA, Halama N, Patsouris E, Konstantinidou AE. Microglia Activation in the Midbrain of the Human Neonate: The Effect of Perinatal Hypoxic-Ischemic Injury. J Neuropathol Exp Neurol 2022; 81:208-224. [PMID: 35092294 DOI: 10.1093/jnen/nlab135] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Perinatal hypoxia-ischemia (PHI) is a major risk factor for the development of neuropsychiatric deficits later in life. We previously reported that after prolonged PHI, the dopaminergic neurons of the human neonate showed a dramatic reduction of tyrosine hydroxylase (TH) in the substantia nigra, without important signs of neuronal degeneration despite the significant reduction in their cell size. Since microglia activation could precede neuronal death, we now investigated 2 microglia activation markers, ionized calcium-binding adapter molecule 1 (Iba1), and the phagocytosis marker Cd68. The highest Iba1 immunoreactivity was found in neonates with neuropathological lesions of severe/abrupt PHI, while the lowest in subjects with moderate/prolonged or older PHI. Subjects with very severe/prolonged or chronic PHI showed an increased Iba1 expression and very activated microglial morphology. Heavy attachment of microglia on TH neurons and remarkable expression of Cd68 were also observed indicating phagocytosis in this group. Females appear to express more Iba1 than males, suggesting a gender difference in microglia maturation and immune reactivity after PHI insult. PHI-induced microglial "priming" during the sensitive for brain development perinatal/neonatal period, in combination with genetic or other epigenetic factors, could predispose the survivors to neuropsychiatric disorders later in life, possibly through a sexually dimorphic way.
Collapse
Affiliation(s)
- Maria T Panayotacopoulou
- From the Department of Psychiatry, National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P).,University Mental Health, Neurosciences and Precision Medicine Research Institute "Kostas Stefanis", National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P, EP)
| | - Ismini Papageorgiou
- Institute for Diagnostic and Interventional Radiology, University Hospital of Jena, Jena, Germany (IP).,Institute of Radiology, Südharz Hospital Nordhausen, Nordhausen, Germany (IP)
| | - Marianna Pagida
- From the Department of Psychiatry, National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P).,University Mental Health, Neurosciences and Precision Medicine Research Institute "Kostas Stefanis", National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P, EP)
| | - Alexandra E Katsogridaki
- From the Department of Psychiatry, National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P).,University Mental Health, Neurosciences and Precision Medicine Research Institute "Kostas Stefanis", National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P, EP)
| | - Margarita Chrysanthou-Piterou
- From the Department of Psychiatry, National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P).,University Mental Health, Neurosciences and Precision Medicine Research Institute "Kostas Stefanis", National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P, EP)
| | - Nektarios A Valous
- Applied Tumor Immunity Clinical Cooperation Unit, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany (NAV)
| | - Niels Halama
- Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany (NH).,Division of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany (NH)
| | - Efstratios Patsouris
- University Mental Health, Neurosciences and Precision Medicine Research Institute "Kostas Stefanis", National and Kapodistrian University of Athens, Athens, Greece (MTP, MP, AEK, MC-P, EP).,1st Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece (EP, AEK)
| | | |
Collapse
|
2
|
Vidyadhara DJ, Yarreiphang H, Raju TR, Alladi PA. Differences in Neuronal Numbers, Morphology, and Developmental Apoptosis in Mice Nigra Provide Experimental Evidence of Ontogenic Origin of Vulnerability to Parkinson's Disease. Neurotox Res 2021; 39:1892-1907. [PMID: 34762290 DOI: 10.1007/s12640-021-00439-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 10/26/2021] [Accepted: 10/29/2021] [Indexed: 10/19/2022]
Abstract
Parkinson disease (PD) prevalence varies by ethnicity. In an earlier study, we replicated the reduced vulnerability to PD in an admixed population, using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-susceptible C57BL/6 J, MPTP-resistant CD-1 and their F1 crossbreds. In the present study, we investigated if the differences have a developmental origin. Substantia nigra was evaluated at postnatal days 2 (P2), P6, P10, P14, P18, and P22. C57BL/6 J mice had smaller nigra and fewer dopaminergic neurons than the CD-1 and crossbreds at P2, which persisted through development. A significant increase in numbers and nigral volume was observed across strains until P14. A drastic decline thereafter was specific to C57BL/6 J. CD-1 and crossbreds retained their numbers from P14 to stabilize with supernumerary neurons at adulthood. The neuronal size increased gradually to attain adult morphology at P10 in the resistant strains, vis-à-vis at P22 in C57BL/6 J. Accordingly, in comparison to C57BL/6 J, the nigra of CD-1 and reciprocal crossbreds possessed cytomorphological features of resilience, since birth. The considerably lesser dopaminergic neuronal loss in the CD-1 and crossbreds was seen at P2 and P14 and thereafter was complemented by attenuated developmental cell death. The differences in programmed cell death were confirmed by reduced TUNEL labelling, AIF, and caspase-3 expression. GDNF expression aligned with the cell death pattern at P2 and P14 in both nigra and striatum. Earlier maturity of nigra and its neurons appears to be better features that reflect as MPTP resistance at adulthood. Thus, variable MPTP vulnerability in mice and also differential susceptibility to PD in humans may arise early during nigral development.
Collapse
Affiliation(s)
- D J Vidyadhara
- Department of Neurophysiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, 560029, India
- Departments of Neurology and Neuroscience, Yale University School of Medicine, New Haven, CT, USA
| | - Haorei Yarreiphang
- Department of Neurophysiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, 560029, India
| | - Trichur R Raju
- Department of Neurophysiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, 560029, India
| | - Phalguni Anand Alladi
- Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, 560029, India.
- Formerly at Department of Neurophysiology, National Institute of Mental Health and Neuro-Sciences, Hosur Road, Bangalore, India.
| |
Collapse
|